To obtain an MCP-1 receptor antagonist useful for inflammatory disease or organopathy relating to MCP-1 by including an organic germanium compound as an active component.
This MCP-1 receptor antagonist contains an organic germanium compound of formula: [(O1/2)3Ge-A-CO2H]n {(n)≥1; A is a lower alkyl}, preferably 3-oxygelmyl propionic acid 8-membered structural material of the formula {R is -CH2CH2COOH, (m) is weight-average molecular weight of 137±84 reduced from weight-average molecular weight of propagermanium propyl ester}, the minimum structural unit (O1/2)3GeCH2CH2COOH, an empirical formula: C6H10Ge2 O7 as an active component. When the medical agent is administrated to a human, preferably 1-1,500 mg per day and 60-120 mg per day in a peroral administration to an adult of 50 kg weight.
YOKOCHI SHOJI
HASHIMOTO HIROYUKI
AWATANI JUICHI
